Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:2.7.7.7 (
DNA polymerase
)
17,007
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The kinetics of the inhibition of DNA polymerases-alpha and -beta from sea urchin embryos by
pyridoxal 5-phosphate
were studied. The inhibition of DNA polymerase-alpha activity by
pyridoxal 5-phosphate
was competitive with activated DNA but noncompetitive with each deoxynucleoside triphosphate. With poly(dC)-oligo(dG)12-18 as a template-primer, however, the inhibition of DNA polymerase-alpha was competitive with dGTP but noncompetitive with the template-primer. These results suggest that DNA polymerase-alpha interacts with activated DNA and poly(dC)-oligo(dG)12-18 in different ways. The inhibition of
DNA polymerase
-beta by
pyridoxal 5-phosphate
was competitive with deoxynucleoside triphosphate using activated DNA as a template-primer and noncompetitive with activated DNA. Using poly(rA)-oligo(dT)12-18 as a template-primer,
DNA polymerase
-beta activity yielded sigmoid curves against both dTTP and the template-primer concentrations and was inhibited by
pyridoxal 5-phosphate
noncompetitively with respect to both dTTP and the template-primer. These results indicate that the inhibitory mode of DNA polymerase-alpha by
pyridoxal 5-phosphate
is different from that of
DNA polymerase
-beta.
...
PMID:The mode of inhibitory action by pyridoxal 5-phosphate on DNA polymerase-alpha and -beta. 50 44
We have labeled the large fragment of Escherichia coli
DNA polymerase I
(Pol I) with pyridoxal 5'-phosphate, a substrate binding site directed reagent for DNA polymerases [Modak, M. J. (1976) Biochemistry 15, 3620-3626]. A covalent attachment of
pyridoxal phosphate
to Pol I results in the loss of substrate binding as well as the polymerase activity. The inactivation was found to be strictly dependent on the presence of a divalent metal ion. Four moles of
pyridoxal phosphate
was found to react per mole of the enzyme, while in the presence of substrate deoxynucleoside triphosphate only 3 mol of
pyridoxal phosphate
was bound. To identify the substrate-protected site on the enzyme, tryptic peptides from enzyme labeled with
pyridoxal phosphate
and tritiated borohydride, in the presence and absence of substrate, were resolved on a C-18 reverse-phase column. A single peptide containing the substrate-protected site was identified and further purified. The amino acid composition and sequence analysis of this peptide revealed it to span residues 756-775 in the primary acid sequence of Pol I. Lys-758 of this sequence was found to be the site of the
pyridoxal phosphate
reaction. It is therefore concluded that Lys-758 is the site of binding for the metal chelate form of nucleotide substrates in E. coli
DNA polymerase I
.
...
PMID:Identification and amino acid sequence of the deoxynucleoside triphosphate binding site in Escherichia coli DNA polymerase I. 329 33
We have shown that pyridoxal 5'-phosphate is an effective inhibitor of Rauscher leukemia virus
DNA polymerase
(Biochemistry 15 (1976) 3620). Detailed studies of this inhibition revealed that, in addition to the phosphate and aldehyde groups of
pyridoxal phosphate
, the presence of a divalent cation is essential for the inhibitory action. The synthesis directed by template primers containing GC base-pairs exhibited more resistance to
pyridoxal phosphate
inhibition than did that directed by AT base-paired templates. Maximal inhibitory activity of
pyridoxal phosphate
, however, is noted in the presence of Mn2+, irrespective of which template-primer is used to direct the DNA synthesis. The action of
pyridoxal phosphate
on the substrate binding site may be deduced from the observations that: (a) only the substrate triphosphate is able to reverse the
pyridoxal phosphate
-mediated inhibition; (b) the inhibition kinetics exhibit a classical competitive pattern with the substrate; (c) analogous to substrate deoxynucleoside triphosphates the inhibitor is also accepted only in the form of its divalent metal ion complex; and (d) substrate site-specific labeling of RLV
DNA polymerase
has been shown to occur by linking covalently the
pyridoxal phosphate
bound to a lysine residue at the substrate binding site.
...
PMID:Divalent cation-dependent pyridoxal 5'-phosphate inhibition of Rauscher leukemia virus DNA polymerase: characterization and mechanism of action. 728 79
Pyridoxal phosphate modification of adenovirus
DNA polymerase
results in loss of
DNA polymerase
activity, whereas the 3' --> 5' exonuclease activity is unaffected. Inhibition by
pyridoxal phosphate
is time-dependent, displays saturation kinetics, and is reversible in the presence of excess primary amine unless the
pyridoxal phosphate
-enzyme adduct is first reduced with NaBH4. Thus, inhibition is the consequence of Schiff base formation between the aldehyde moiety of
pyridoxal phosphate
and primary amino groups on the enzyme. In addition to inhibiting
DNA polymerase
activity,
pyridoxal phosphate
also inhibited the ability of the enzyme to initiate viral DNA replication, by transfer of dCMP onto the preterminal protein. Neither template-primer nor dNTP protect against
pyridoxal phosphate
inhibition, but the combination of template-primer and complementary substrate dNTP protected both initiation and
DNA polymerase
activities. Thus, it is likely that both the dCMP transfer activity required for initiation and
DNA polymerase
activity are carried out at the same site of the enzyme.
...
PMID:Pyridoxal 5'-phosphate inhibition of adenovirus DNA polymerase. 879 69